HIGHLIGHTS
en Cáncer de Próstata

ASCO 2019

Highlights comentados por:
Dr. José Pablo Maroto Ruiz
Oncólogo en Hospital Sant Pau, Barcelona.
Enfermedad metastásica: Hormonosensible

Enfermedad metastásica: Hormonosensible

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Enfermedad localizada

Enfermedad localizada

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).

Enfermedad M0

Enfermedad M0

Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).